##common.pageHeaderLogo.altText##

Vol. 5 No. 02 (2025)

The Effectiveness of Levonorgestrel Releasing Intrauterine System in The Treatment in Premenopausal Age with Heavy Menstrual Bleeding

Clinical Medicine And Health Research Journal, Vol. 5 No. 02 (2025), 18 March 2025 , Page 1194-1201
https://doi.org/10.18535/cmhrj.v5i02.454

Abstract

Background: Endometrial hyperplasia is the abnormal proliferation of endometrial glands due to unopposed estrogen stimulation, often leading to an increased risk of endometrial cancer. The condition is more common than endometrial cancer, particularly in women aged 40-45 for hyperplasia without atypia and 45- 55 for atypical hyperplasia. LNG-IUS reduces hyperplasia risk by differentiating epithelial cells and preventing estrogen-induced proliferation.


Aims of the study: To estimate the effectiveness of LNG-IUS in treating heavy menstrual bleeding in premenopausal women.


Subjects and Methods: A prospective observational study was conducted at Basrah Maternity and Children Hospital and the private clinic of my supervisor during the period from 1st of June 2023 to 1st of September 2024. It involved 69 premenopausal women with heavy menstrual bleeding (HMB) treated with the LNG-IUS. Participants were screened for eligibility, underwent assessments, and were monitored for menstrual blood loss, side effects, and haemoglobin levels at 4, 12, and 24 weeks post-insertion.


Results: The study involved 66 premenopausal women using LNG-IUS, 83.0% of the studied patients with HMB who inserted mirena have marked improvement at the end of the study of 24 weeks post insertion. Median Pictorial blood assessment score chart (PBAC) scores significantly reduced from a pre-insertion score of 290 to 160 at 4 weeks, 85 after 12 weeks and 22 after 24 weeks (p < 0.001). Haemoglobin levels improved from 8.6 ± 0.4 to 10.9 ± 1.2 mg/dl, and serum ferritin rose from 23 ± 16.3 to 65 ± 20.3 ng/ml (both p < 0.001). Common side effects included withdrawal bleeding (31.8%) and vaginal discharge (25.7%).


Conclusion: The LNG-IUS significantly reduced menstrual blood loss, improved symptoms in 83% of women, and had a low expulsion rate of the device, and significant increase in haemoglobin and serum ferritin levels following LNG-IUS insertion, indicating effective treatment for HMB.

How to Cite

al -Rubaai, S. ., Husain, S. M. ., & Alwan Al-Quraishi, H. A. . (2025). The Effectiveness of Levonorgestrel Releasing Intrauterine System in The Treatment in Premenopausal Age with Heavy Menstrual Bleeding. Clinical Medicine And Health Research Journal, 5(02), 1194–1201. https://doi.org/10.18535/cmhrj.v5i02.454

Download Citation

References

  • Parkash V, Fadare O, Tornos C, McCluggage WG. Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2015;126(4):897.
  • van der Meer AC, Hanna LS. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clin Obes. 2017;7(1):54-57.
  • Endometrial hyperplasia (thick endometrium) [Internet]. Indira IVF. [cited 2024 Mar 3]. Available from: https://www.indiraivf.com/blog/endometrial-hyperplasia-thick-endometrium-meaning-causes-treatment
  • Singh G, Puckett Y. Endometrial Hyperplasia. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560693/
  • Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, Wallwiener M. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022;306(2):407-421.
  • Endometrial hyperplasia [Internet]. Cleveland Clinic. [cited 2024 Feb 20]. Available from: https://my.clevelandclinic.org/health/diseases/16569-atypical-endometrial-hyperplasia
  • Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;2012(8):CD000402.
  • Niskakoski A, Pasanen A, Porkka N, Eldfors S, Lassus H, Renkonen-Sinisalo L, Kaur S, Mecklin JP, Bützow R, Peltomäki P. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. Gynecol Oncol. 2018;150(1):92-98.
  • Mills AM, Sloan EA, Thomas M, Modesitt SC, Stoler MH, Atkins KA, Moskaluk CA. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. Am J Surg Pathol. 2016;40(2):155-65.
  • Thomas L. Diagnosis of endometrial hyperplasia [Internet]. News-Medical. 2017 [cited 2024 Mar 9]. Available from: https://www.news-medical.net/health/Diagnosis-of-endometrial-hyperplasia.aspx
  • Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232-254.
  • Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011;3:127–32.
  • Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;9(9):CD012658.
  • Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019;221(5):474.e1-474.e11.
  • Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang Y-B, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18.
  • Jordan SJ, Na R, Weiderpass E, Adami H-O, Anderson KE, van den Brandt PA, et al. Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2021;148(9):2068–78.
  • Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015;213(4):469–78.
  • Lethaby A, Munawar H, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No: CD002126.
  • Lacey JV, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DA, Chatterjee N, Langholz B. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010;28(5):788-92.
  • Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Womens Health (Lond). 2016;12(1):27-34.
  • Desai RM. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health. 2012;3(1):20-3.
  • Dhamangaonkar PC, Anuradha K, Saxena A. Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding. J Midlife Health. 2015;6(1):26-30.
  • Zhang J, Zhu C, Yan L, Wang Y, Zhu Q, He C, et al. Comparing levonorgestrel intrauterine system with hysteroscopic niche resection in women with postmenstrual spotting related to a niche in the uterine cesarean scar: a randomized, open-label, controlled trial. Am J Obstet Gynecol. 2023;228(6):712.e1-712.e16.
  • Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011; 83(3):242-7.
  • Park DS, Kim ML, Song T, Yun BS, Kim MK, Jun HS, Seong SJ. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiwan J Obstet Gynecol. 2015; 54(4):412-5.
  • Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116(1):35-8.
  • Wrona W, Stępniak A, Czuczwar P. The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids. Prz Menopauzalny. 2017;16(4):129-132.
  • Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E. The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet. 2012;285(1):117-21.
  • Nidhi, Kumari A, Tirkey S, Prakash J. Effectiveness of Levonorgestrel Releasing Intrauterine System in Perimenopausal Women with Heavy Menstrual Bleeding: A Prospective Study at a Teaching Hospital in India. J Menopausal Med. 2022;28(3):128-135.
  • Archer DF, Mansour D, Foidart JM. Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview. J Clin Med. 2022;11(15):4634.
  • Hochmuller JT, Lopes KS, Guazzelli CAF, Gomes MKO, Araujo Júnior E, Peixoto AB. Expulsion rate of intrauterine device: mediate vs. immediate puerperium period. J Turk Ger Gynecol Assoc. 2020;21(3):143-149.
    • Article Viewed: 0 Total Download

    ##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##

    Cover Image

    Information